HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Cognition Therapeutics to a loss of $0.06 per share from a projected loss of $0.07, while maintaining a “Buy” rating.
• Analyst sentiment is mixed but leans positive: three analysts rate CGTX a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $3.33.
• Cognition Therapeutics recently reported a Q2 loss of $0.04 per share, beating estimates by $0.02; institutional investors own 43.35% of the stock, which recently traded near $1.01.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Investment analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for Cognition Therapeutics in a research note issued on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.06) per share for the quarter, up from their previous estimate of ($0.07). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Cognition Therapeutics' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cognition Therapeutics' Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.20) EPS.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Cognition Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cognition Therapeutics in a report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $3.33.

Cognition Therapeutics Price Performance

NASDAQ CGTX opened at $1.01 on Monday. The company has a market cap of $96.04 million, a P/E ratio of -5.94 and a beta of 1.78. Cognition Therapeutics has a 12 month low of $0.55 and a 12 month high of $3.83. The company has a 50-day moving average of $1.10 and a 200-day moving average of $1.11.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02.

Hedge Funds Weigh In On Cognition Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Tocqueville Asset Management L.P. purchased a new position in shares of Cognition Therapeutics during the 2nd quarter valued at approximately $369,000. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Cognition Therapeutics in the second quarter worth $165,000. BlackRock Inc. bought a new stake in shares of Cognition Therapeutics in the second quarter worth $1,451,000. Bryn Mawr Trust Advisors LLC acquired a new stake in Cognition Therapeutics in the second quarter valued at $33,000. Finally, Renaissance Technologies LLC raised its holdings in Cognition Therapeutics by 15.2% in the first quarter. Renaissance Technologies LLC now owns 1,117,136 shares of the company's stock valued at $848,000 after acquiring an additional 147,623 shares in the last quarter. 43.35% of the stock is owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer's disease. The company's lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer's disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source